Clinical Research

Epidiolex has positive Phase 3 results

Epidiolex, a cannabinoid drug for a type of childhood epilepsy known as Dravet syndrome has reduced the frequency of seizures in a Phase 3 trial of children and adolescents with the disease, all of whom were not getting relief from current treatments.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

Tecentriq misses endpoint in trial

The Roche Group’s checkpoint antibody, Tecentriq (atezolizumab), has missed the primary endpoint of overall survival in a Phase 3 trial, designed to confirm the drug’s efficacy in urothelial cancer and convert an earlier accelerated approval in the US to a full approval.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Switzerland

AstraZeneca asthma compound fails trial

The first of two pivotal Phase 3 trials of a new anti-interleukin-13 drug for severe asthma has failed to meets its primary endpoint of a significant reduction in the annual asthma exacerbation rate, AstraZeneca Plc announced on 10 May.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

Poxel diabetes drug succeeds in Japan trial

Poxel SA has reported positive data from a Phase 2b study in Japan of imeglimin, its treatment for Type 2 diabetes. The primary endpoint of the trial was met, and was more pronounced in the Japanese patients than had been the case in similar Phase 2b trials in the US and the EU.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

France

Laquinimod fails to meet endpoint in MS trial

A Phase 3 trial of an experimental drug for relapsing-remitting multiple sclerosis, laquinimod, has failed to meet its primary endpoint which was to show an improvement in the time to confirmed disease progression.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Sweden

Roche says Alecensa more effective than rival drug in lung cancer

Roche said that its kinase inhibitor Alecensa (alectinib) has produced better results in a Phase 3 trial of patients with a specific type of lung cancer than a rival treatment marketed by Pfizer Inc.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Switzerland

Positive data for HDAC inhibitor - Medivir

Sweden-based Medivir AB has reported positive Phase 2 data for a recently acquired histone deacetylase (HDAC) inhibitor in a trial of patients with early-stage cutaneous T cell lymphoma (CTCL), a haematologic cancer that presents in the skin.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Sweden

Sirukumab trial results in The Lancet

A Phase 3 trial in which patients with active rheumatoid arthritis (RA) were treated with the monoclonal antibody sirukumab, or placebo, met its primary endpoint of relief from swelling even in those who had failed to respond to two or more biological drugs.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United States

Pancreatic cancer trial suspended

An early clinical trial of a candidate treatment for pancreatic cancer developed by Halozyme Therapeutics Inc has been suspended after the independent data monitoring committee determined that it was unlikely to improve the patients’ overall survival.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United States

Daratumumab study in non-Hodgkin’s lymphoma stopped

A Phase 2 study of the monoclonal antibody daratumumab in three types of non-Hodgkin’s lymphoma has been stopped early because it failed to reach predefined targets for overall response, Genmab A/S announced on 30 March.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Denmark

Syndicate content